Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Exubera inhaled insulin: Long-term study; Phase III

In a Phase III trial in 145 patients, significantly more patients receiving Exubera achieved the primary endpoint of HbA1c levels of 8%

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE